A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2335-2339

  Drevs, Joachim ^a   Medinger, Michael ^a   Mross, Klaus ^a   Fuxius, Stefan ^b   Hennig, Juergen ^a   Buechert, Martin ^a   Thomas, Anne ^c   Unger, Clemens ^a   Chen, Bee Lian ^d   Lebwohl, David ^d   Laurent, Dirk ^e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Leicester Royal Infirmary ^*  (Germany)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

^e BAYER PHARMA AG   (Germany)

Author keywords

Angiogenesis; DCE MRI; MTD; PTK ZK; VEGF

Indexed keywords

ANTIHYPERTENSIVE AGENT; BASIC FIBROBLAST GROWTH FACTOR; GADOLINIUM; VASCULOTROPIN; VATALANIB;

ABDOMINAL PAIN; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BACKACHE; BIOLOGICAL ACTIVITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; HYPERHIDROSIS; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SPEECH DISORDER; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS; PHTHALAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955072956     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Plate KH, Vreier G and Risau W: Molecular mechanisms of development and tumor angiogenesis. Brain Pathol 4: 207-218, 1994. (Pubitemid 24261926)
2. Fan TBD, Jaggar R and Bicknell R: Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. TIPS 16: 57 66, 1995.
3. Sitaras NM, Sariban E, Bravo M, Pantazis P and Antoniades HN: Constitutive production of platelet-derived growth factor-like proteins by human prostate carcinoma cell lines. Cancer Res 48: 1930-1935, 1988.
4. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W and Nagy A: Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380: 435-439, 1996.
5. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G and Totzke F: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189, 2000.
6. Drevs J, Hofmann I, Hugenschmidt H, Wittig C, Madjar H, Müller M, Wood J, Martiny-Baron G, Unger C and Marmé D: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res 60: 4819-4824, 2000.
7. Drevs J, Müller-Driver R, Wittig C, Fuxius S, Esser N, Hugenschmidt H, Konerding MA, Allegrini PR, Wood J, Hennig J, Unger C and Marmé D: PTK787/ZK 222584, a specific endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 62: 4015-4022, 2002.
8. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI, Mross K, Medinger M, Lee L, Pinheiro J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan M and Marmé D: Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 16: 558-565, 2005.
9. Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson E, Puccio-Pick M, Laurent D and Steward WP: Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 23: 4162-4171, 2005.
10. Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A, Cherryman GR, Laurent D, Dugan M, Marmé D and Steward WP: Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21: 3955-3964, 2003.
11. Lee L, Sharma S, Morgan B, Allegrini P, Schnell C, Brueggen J, Cozens R, Horsfield M, Guenther C, Steward WP, Drevs J, Lebwohl D, Wood J and McSheehy PM: Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases. Cancer Chaemother Pharmacol 57: 761-771, 2006.
12. Los M, Roodhart JML and Voest EE: Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12: 443-450, 2007.
13. Mross K, Drevs J, Müller M, Medinger M, Marmé D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Günther C, Laurent D and Unger C: Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 41: 1291-1299, 2005.